EarningsThe guidance for FY25 is a clear positive surprise with adj. EBITDA sitting 20% ahead of the street at mid-point.
Market ShareMarket share gains in the €55bn German Rx market, coupled with strong KPIs that show that new Rx customers are both more profitable and more loyal, make analysts optimistic on the future development of the group.
Regulatory EnvironmentThe recent ruling of the European Court of Justice (ECJ) is a positive, as promotions in the form of a specific amount of money for Rx medication are allowed.